Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate
1. EDIT-401 shows ~90% LDL-C reduction in primate studies. 2. Human proof-of-concept data expected by end of 2026. 3. The company has substantial cash runway into Q2 2027. 4. EDIT-401 targets hyperlipidemia, offering potential lifelong benefits. 5. Market for LDL-C reduction therapies is significant and underserved.